Related Experiment Video
Updated: Aug 8, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Characteristics of methylphenidate dependence syndrome in psychiatric hospital settings
1Department of Drug Dependence Research, National Institute of Mental Health, National Center for Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan.
Abstract:
The characteristics of methylphenidate (MPD) cases reported in a nationwide mental hospital survey on substance-related psychiatric disorders are studied compared to methamphetamine cases. Although the two groups did not differ in terms of age and sex, the MPD group revealed longer educational histories and lower antisocial traits. About half of the MPD group had a history of methamphetamine use and 30% had used the substance as the initial substance of abuse. They exhibited a general tendency toward multiple substance use. These results indicate that a significant number of MPD cases exist who used MPD as a substance alternative to methamphetamine and also suggest that they may potentially have a tendency to develop abuse or dependence. The MPD cases most likely had a psychiatric diagnosis of "Dependence syndrome (F15.2)," according to the ICD-10 guidelines. The SDS scores also indicated a more severe dependence syndrome, particularly psychological dependence, which they may possibly develop more quickly. An abundance of information for MPD abusers to utilize is available through the internet, including the pharmacological properties, such as increased sensation or elation through MPD intake and how and where to easily acquire the substance. They may even forge a prescription to obtain MPD. This behavior can be recognized as "substance-seeking behavior" in behavioral pharmacology terms, accompanied by craving based on psychological dependence on the substance, and can be very difficult to control. Little evidence exists regarding the effectiveness and necessity of MPD as a treatment for depression, and thus MPD prescriptions must be carefully considered by psychiatrists or physicians. The application of MPD as an antidepressant in the health insurance system must be re-examined as well.
Insights
Methylphenidate (MPD) abuse is a growing concern, often used as a methamphetamine alternative. MPD dependence can develop quickly, necessitating careful prescription practices.
Area of Science:
- Psychiatry
- Pharmacology
- Criminology
Background:
- Methylphenidate (MPD) is increasingly reported in substance-related psychiatric disorders.
- Comparison with methamphetamine (MA) cases is crucial for understanding MPD abuse patterns.
Purpose of the Study:
- To characterize methylphenidate (MPD) cases in substance-related psychiatric disorders.
- To compare MPD cases with methamphetamine (MA) cases.
- To explore the potential for MPD abuse and dependence.
Main Methods:
- Nationwide mental hospital survey on substance-related psychiatric disorders.
- Comparative analysis of MPD and MA user characteristics.
- ICD-10 diagnostic criteria and SDS scores for dependence assessment.
Main Results:
- MPD users had longer education and fewer antisocial traits than MA users.
- Half of MPD users had prior MA use; 30% initiated abuse with MPD.
- MPD cases frequently exhibited "Dependence syndrome (F15.2)" with severe psychological dependence.
Conclusions:
- MPD is used as a methamphetamine alternative, with potential for rapid abuse and dependence.
- Substance-seeking behavior and craving are significant in MPD dependence.
- MPD's role in depression treatment and insurance coverage requires re-evaluation due to limited evidence and abuse potential.
Related Concept Videos
Drug Dependence
Drug Abuse and Addiction: Pharmacological Phenomena
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
